alexa Biosimilar Drugs Market Future Trends in United States | Open Access Journals
ISSN : 2153-2435
Pharmaceutica Analytica Acta
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Biosimilar Drugs Market Future Trends in United States

Barkha G1* and Praneeth K2

1Amity Institute of Biotechnology, Amity University, Noida, India

2Department of Pharmaceutical sciences, The University of Greenwich, London, UK

*Corresponding Author:
Barkha G
Amity Institute of Biotechnology, Amity University, Noida, India
Tel:
011-22932958
E-mail: [email protected]

Received Date: March 14, 2016; Accepted Date: April 19, 2016; Published Date: April 22, 2016

Citation: Barkha G, Praneeth K (2017) Biosimilar Drugs Market Future Trends in United States. Pharm Anal Acta 8:543. doi: 10.4172/2153-2435.1000543

Copyright: © 2017 Barkha G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta

Abstract

USA is a largest market of biologics globally. Biosimilar market expected to represent CAGR of 62.2 % as the chances of growth of biosimilar market from $1.7 billion in 2014 to $30 billion by 2020. Currently USA is a very small market for biosimilar but it can grow as the largest contributor for biosimilars as major share (upto 10 %) of the global revenue is generated from USA. Biosimilar therapy is a very effective way of treating disease conditions like cancer, rheumatoid, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and many autoimmune disorders [1].

Commentary

USA is a largest market of biologics globally. Biosimilar market expected to represent CAGR of 62.2 % as the chances of growth of biosimilar market from $1.7 billion in 2014 to $30 billion by 2020. Currently USA is a very small market for biosimilar but it can grow as the largest contributor for biosimilars as major share (upto 10 %) of the global revenue is generated from USA. Biosimilar therapy is a very effective way of treating disease conditions like cancer, rheumatoid, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and many autoimmune disorders [1].

Pressure is generated on biosimilar market due to average pricing discount from past few tenders. This condition can be regulated by many government supports. Trend of biosimilar in the market of America has been developed by the approval and regulatory process [2-4]. In 2010, patient care act was passed by Obama which give licensure pathway for interchangeable products, which provided under the part of Biologics Price Competition and Innovation Act for the product demonstrating as biosimilar, manufacturers need to submit Biologics License Application (BLA) [2].

Target reference products for the USA market are Monoclonal Antibodies (MAbs), recombinant protein and some high-purity protein products, out of which recombinant therapeutic with large market (sales) even with small profitable amount. USA has approximate patent expiration date of 15 years for innovator drug after which it becomes susceptible to biosimilar competition by 2020. About 119 recombinant proteins marketed out of which 30 are susceptible to biosimilar. There are ≥10 biosimilars USA Company reported in development. Overall 15% increase in business is reported by Contract Manufacturing Organizations (CMOs) from biosimilars launch in USA market.

Major products of USA biosimilar markets are Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin alpha. Key players for USA Biosimilar product markets are Sandoz, Amgen, Teva Pharmaceutical Industries, Hospira, STADA Arzneimittel, Mylan [4,5].

There are 10-260 biosimilars under pipeline as per CMO, by the report of center of drug evaluation and research 4-6 licensed biological products are interchangeable (11/23/2016).

Any size and type of company can enter in biosimilar market but competition will be high for the drivers with the greatest number of innovator drug.

As per the report of IMS Institute for Health Informatics (2015), 41 biosimilars are under development out of which 23 biosimilars are ready to be released into market [6]. A large number of biosimilars are in pipeline and are predicted to be marketed soon [7]. M923, a biosimilar HUMIRA (adalimumab) under the phase-III trial and will be marketed soon by Momenta. Sandoz being more experienced in the industry was the first to get approval of a biosimilar in the US as per the new FDA biosimilars pathway established under the BPCIA [8]. Many crucial biosimilar are under pipeline by Teva Inc. including TVB018 CT-P10 (Rituxan), CT-P6 (Herceptin) and have received approval for tbo-filgrastim (XM02 filgrastim) by USFDA [9]. Herceptin is targeted by Mylan with the submission of FDA biosimilar approval. Another market driver Pfizer has introduced Remicade biosimilar at 15% discount in USA [10-12].

Biosimilar has almost 8% of patients throughout the world due to high price. However, manufacturing cost is high compared to biologics and establishment of biosimilar is a real time challenge for pharmaceutical companies at affording price for the class of patients and treatment. Competition for the biosimilar development is accelerating with high speed due to consistent demand worldwide [13,14]. They are highly complex biomolecules small change in production can lead to major implication in safety. USA has greatest opportunities for biosimilars as biologics has higher price. Biosimilars are high potential for the pharmaceutical market due to physician acceptance owing to low risk of challenging immunity and diligence [15].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 837
  • [From(publication date):
    April-2017 - Oct 24, 2017]
  • Breakdown by view type
  • HTML page views : 772
  • PDF downloads :65
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords